Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

Antiviral therapy in a child with pediatric human immunodeficiency virus (HIV): case study of audiologic findings.

J Am Acad Audiol. 1998 Aug;9(4):292-8. Unique Identifier : AIDSLINE MED/98402075
Christensen LA; Morehouse CR; Powell TW; Alchediak T; Silio M; Department of Communication Disorders, Louisiana State University; Medical Center, New Orleans 70112, USA.

Abstract: Over the past decade, much research has been conducted to determine the auditory consequences of human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS). This research, primarily using adult patients, has focused on the involvement of the central auditory nervous system (CANS). Measures of auditory evoked potentials, particularly the auditory brainstem response (ABR), can document changes in the CANS as the disease progresses and during treatment with antiviral therapies such as zidovudine (AZT) and didanosine (ddI). This case study presents the audiologic findings for a child with HIV infection. Evaluations were performed over a 2-year period prior to the initiation of antiviral therapy and following treatment. Audiologic measures included behavioral audiometry, tympanometry, otoacoustic emissions, and ABR latency/intensity functions and rate studies. Findings indicated a gradual shortening of all ABR component latencies following the initiation of antiviral therapy. In addition, a high-frequency hearing loss was detected during the final evaluation subsequent to 19 months of treatment with AZT and ddI.

Keywords: JOURNAL ARTICLE Anti-HIV Agents/*ADVERSE EFFECTS Child Evoked Potentials, Auditory, Brain Stem Female Hearing Loss, High-Frequency/*CHEMICALLY INDUCED/DIAGNOSIS Hearing Loss, Sensorineural/*CHEMICALLY INDUCED/DIAGNOSIS Human HIV Seropositivity/*COMPLICATIONS/*DRUG THERAPY Photic Stimulation Severity of Illness Index Support, Non-U.S. Gov't Zidovudine/*THERAPEUTIC USE
990330
A9931112

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .